Earlitec Diagnostics Announces $19.5 Million Financing To Advance Autism Diagnosis And Treatment In Children As Young As 16 Months Of Age

Feb 18, 2022•over 3 years ago

Amount Raised

$19.5 Million

Atlanta

Description

EarliTec Dx, Inc. (“EarliTec”), a digital health company developing novel diagnostic and therapeutic products for children with Autism Spectrum Disorder (ASD) and early childhood vulnerabilities, announced today a $19.5 million financing to further its mission of making earlier ASD identification and treatment accessible to children everywhere. Bernie Marcus led the Series A round with participation from the Georgia Research Alliance (GRA).

Company Information

Company

Earlitec Diagnostics

Location

Atlanta, Georgia, United States

About

EarliTec Diagnostics is a digital health company making earlier identification and treatment for ASD and related disabilities accessible to children everywhere. Developed by leading researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine and Yale University, EarliTec is pioneering development of biomarkers that help parents, providers and caregivers understand how a child is viewing the world. The company’s initial product, the EarliPoint® Evaluation for Autism Spectrum Disorder received breakthrough status from the FDA as it seeks to be the first objective, clinically validated measure of individual ASD status and severity in children as young as 16 months of age.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech